DE69317856D1 - Ein Verfahren zur Herstellung von Finasteride - Google Patents

Ein Verfahren zur Herstellung von Finasteride

Info

Publication number
DE69317856D1
DE69317856D1 DE69317856T DE69317856T DE69317856D1 DE 69317856 D1 DE69317856 D1 DE 69317856D1 DE 69317856 T DE69317856 T DE 69317856T DE 69317856 T DE69317856 T DE 69317856T DE 69317856 D1 DE69317856 D1 DE 69317856D1
Authority
DE
Germany
Prior art keywords
finasteride
magnesium halide
disclosed
production
androst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69317856T
Other languages
English (en)
Other versions
DE69317856T2 (de
Inventor
Ulf H Dolling
James A Mccauley
Richard J Varsolona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26681536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69317856(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE69317856D1 publication Critical patent/DE69317856D1/de
Application granted granted Critical
Publication of DE69317856T2 publication Critical patent/DE69317856T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic System without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00—Details of television systems
    • H04N5/74—Projection arrangements for image reproduction, e.g. using eidophor
    • H04N5/7416—Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal
    • H04N5/7458—Projection arrangements for image reproduction, e.g. using eidophor involving the use of a spatial light modulator, e.g. a light valve, controlled by a video signal the modulator being an array of deformable mirrors, e.g. digital micromirror device [DMD]
DE69317856T 1992-11-19 1993-11-12 Ein Verfahren zur Herstellung von Finasteride Expired - Lifetime DE69317856T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97853592A 1992-11-19 1992-11-19
US08/010,734 US5468860A (en) 1992-11-19 1993-01-29 New finasteride processes

Publications (2)

Publication Number Publication Date
DE69317856D1 true DE69317856D1 (de) 1998-05-14
DE69317856T2 DE69317856T2 (de) 1998-11-05

Family

ID=26681536

Family Applications (4)

Application Number Title Priority Date Filing Date
DE0599376T Pending DE599376T1 (de) 1992-11-19 1993-11-12 Ein Verfahren zur Herstellung von Finasteride.
DE0655458T Pending DE655458T1 (de) 1992-11-19 1993-11-12 Neues Verfahren zur Herstellung von Finasteriden.
DE69317856T Expired - Lifetime DE69317856T2 (de) 1992-11-19 1993-11-12 Ein Verfahren zur Herstellung von Finasteride
DE69323754T Expired - Fee Related DE69323754T2 (de) 1992-11-19 1993-11-12 Neues Verfahren zur Herstellung von Finasteriden

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE0599376T Pending DE599376T1 (de) 1992-11-19 1993-11-12 Ein Verfahren zur Herstellung von Finasteride.
DE0655458T Pending DE655458T1 (de) 1992-11-19 1993-11-12 Neues Verfahren zur Herstellung von Finasteriden.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69323754T Expired - Fee Related DE69323754T2 (de) 1992-11-19 1993-11-12 Neues Verfahren zur Herstellung von Finasteriden

Country Status (33)

Country Link
US (3) US5468860A (de)
EP (3) EP0823436A3 (de)
JP (2) JPH07110875B2 (de)
CN (1) CN1058018C (de)
AT (2) ATE177112T1 (de)
AU (1) AU658774B2 (de)
BG (2) BG62362B1 (de)
CA (1) CA2103107C (de)
CY (1) CY2135B1 (de)
CZ (3) CZ301160B6 (de)
DE (4) DE599376T1 (de)
DK (2) DK0599376T4 (de)
DZ (1) DZ1733A1 (de)
ES (2) ES2052476T5 (de)
FI (4) FI107450B (de)
GR (4) GR940300045T1 (de)
HK (1) HK1008338A1 (de)
HR (2) HRP931410B1 (de)
HU (2) HU216195B (de)
IL (1) IL107574A (de)
IS (2) IS1692B (de)
LV (2) LV12212B (de)
MX (1) MX9307222A (de)
MY (2) MY110410A (de)
NO (3) NO305912B1 (de)
PH (1) PH31120A (de)
RO (2) RO115165B1 (de)
RU (1) RU2120445C1 (de)
SI (1) SI9300603B (de)
SK (2) SK286488B6 (de)
TW (1) TW257766B (de)
UA (1) UA41341C2 (de)
WO (1) WO1994011387A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes
IT1270660B (it) * 1994-10-13 1997-05-07 Poli Ind Chimica Spa Procedimento microbiologico per la preparazione di 3-oxo-4-azasteroidi-17beta-carbossi sostituiti e uso dei prodotti come inibitori dell'enzima 5alfa-riduttasi
US5670643A (en) * 1995-03-16 1997-09-23 Glaxo Wellcome Inc. Method for preparing finasteride
US5585383A (en) * 1995-05-03 1996-12-17 Merck & Co., Inc. Process for crystallizing a 4-azasteroid 5alpha-reductase inhibitor
EP0859761A4 (de) * 1995-09-15 2000-01-26 Merck & Co Inc 4-azasteroide zur behandlung von hyperandrogenen zuständen
GB2338234B (en) * 1998-06-10 2000-05-03 Torcan Chemical Ltd Preparation of finasteride
ES2153789B1 (es) 1999-07-05 2001-10-16 Raga Consultores S L Procedimiento para la obtencion de 178-(n-terc-butlcarbamoil)-3-ona-4-aza-esteroides
EP1228084A1 (de) * 1999-11-01 2002-08-07 TORCAN CHEMICAL Ltd Verfahren zur herstellung von polymorphischen formen i und ii von finasteride durch komplexierung mit gruppe i oder ii metallsalzen
EP1790653A3 (de) * 2000-09-07 2010-06-02 Dr. Reddy's Laboratories Ltd. Neue polymorphe Form von 17-beta-(n-ter.butyl carbomyol)-4-aza-5- alpha-androst-1-en-3-one und ein Verfahren zu ihrer Herstellung
IL154785A0 (en) * 2000-09-07 2003-10-31 Reddys Lab Ltd Dr Polymorphic form of finasteride and processes for the preparation thereof
KR20030029947A (ko) * 2000-09-07 2003-04-16 닥터 레디스 레보러터리즈 리미티드 17-β-(엔-티-부틸카르바모일)-4-아자-5-α-안드로스트-1-엔-3-온의 신규의다형태 및 그 제조방법
KR100415858B1 (ko) * 2001-09-22 2004-01-24 한미약품 주식회사 17베타-(엔-3차-부틸카바모일)-3-온 스테로이드 화합물의제조방법
CN100428897C (zh) * 2002-08-16 2008-10-29 浙江寿峰堂生物工程有限公司 抗疲劳改善亚健康的保健食品及其制备方法
ES2206065B1 (es) * 2002-10-31 2005-08-16 Ragactives, S.L. Procedimiento para la obtencion de la forma polimorfica i de finasterida.
WO2004083230A1 (en) * 2003-03-19 2004-09-30 Hetero Drugs Limited Novel crystalline forms of finasteride
US7550593B2 (en) * 2003-07-03 2009-06-23 Cipla Limited Process for the preparation of finasteride Form I
US20050136015A1 (en) * 2003-12-17 2005-06-23 McKie Derrick B. Topical use of halosalicylic acid derivatives
US20070167477A1 (en) * 2006-01-13 2007-07-19 Mandava Venkata Naga Brahmeswa Processes to prepare finasteride polymorphs
US7531658B2 (en) * 2006-01-20 2009-05-12 Apotex Pharmachem Inc. Process for the preparation of 17-N-substituted-carbamoyl-4-aza-androst-1-en-3-ones
US7687650B2 (en) 2006-02-03 2010-03-30 Jr Chem, Llc Chemical compositions and methods of making them
US7897800B2 (en) 2006-02-03 2011-03-01 Jr Chem, Llc Chemical compositions and methods of making them
US7927614B2 (en) 2006-02-03 2011-04-19 Jr Chem, Llc Anti-aging treatment using copper and zinc compositions
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
US20090076058A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched finasteride
US8273791B2 (en) 2008-01-04 2012-09-25 Jr Chem, Llc Compositions, kits and regimens for the treatment of skin, especially décolletage
US9004752B2 (en) * 2008-05-05 2015-04-14 Abbvie, Inc. Method for evaluating the solubility of a crystalline substance in a polymer
CA2750636C (en) 2009-01-23 2017-07-25 Jr Chem, Llc Rosacea treatments and kits for performing them
US8952057B2 (en) 2011-01-11 2015-02-10 Jr Chem, Llc Compositions for anorectal use and methods for treating anorectal disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
DE3888378T2 (de) * 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
NZ225100A (en) 1987-06-29 1991-09-25 Merck & Co Inc Reaction of steroids (including 4-azasteroids) with a silylating agent in the presence of a quinone to introduce a delta' double bond and silylated intermediates
US5084574A (en) * 1988-04-18 1992-01-28 Merck & Co., Inc. Dehydrogenation process
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
US5021575A (en) 1989-11-13 1991-06-04 Merck & Co., Inc. Method for introducing a 1,2 double bond into azasteroids
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
EP0462662A3 (en) * 1990-06-20 1992-08-19 Merck & Co. Inc. 17beta-n-monosubstituted adamantyl/norbornanyl carbamoyl-4-aza-5alpha-androst-1-en-3-ones and androstan-3-ones
US5091534A (en) 1990-08-27 1992-02-25 Merck & Co., Inc. Trialkylsilyl trifluoromethanesulfonate mediated α-methylenic carbon functionalization of 4-AZA-5α-androstan-3-one steroids
US5120847A (en) † 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
CA2050824A1 (en) * 1990-09-24 1992-03-25 John M. Williams Process for making 3-oxo-4-aza-androst-1-ene 17-.beta.-ketones
US5061801A (en) * 1990-09-24 1991-10-29 Merck & Co., Inc. Intermediate for making 3-oxo-4-aza-androst-1-ene 17β-ketones
US5468860A (en) * 1992-11-19 1995-11-21 Merck & Co., Inc. New finasteride processes

Also Published As

Publication number Publication date
IS1692B (is) 1998-04-20
MY110411A (en) 1998-05-30
FI20010290A (fi) 2001-02-15
MX9307222A (es) 1994-07-29
DK0655458T3 (da) 1999-09-27
NO951986D0 (no) 1995-05-19
BG103170A (en) 1999-09-30
MY110410A (en) 1998-05-30
SK286488B6 (sk) 2008-11-06
IL107574A0 (en) 1994-02-27
JPH09235294A (ja) 1997-09-09
EP0599376B2 (de) 2008-04-16
FI114800B (fi) 2004-12-31
FI116941B (fi) 2006-04-13
CZ126895A3 (en) 1995-12-13
LV12460A (lv) 2000-04-20
NO990468D0 (no) 1999-02-01
SK281765B6 (sk) 2001-07-10
CZ301160B6 (cs) 2009-11-18
FI20040559A (fi) 2004-04-21
CA2103107C (en) 2010-09-28
IS4286A (is) 1994-05-20
BG64464B1 (bg) 2005-03-31
NO990468L (no) 1995-05-19
GR3029554T3 (en) 1999-06-30
EP0599376A2 (de) 1994-06-01
WO1994011387A2 (en) 1994-05-26
FI952422A0 (fi) 1995-05-18
RO115165B1 (ro) 1999-11-30
BG62362B1 (bg) 1999-09-30
BG99637A (bg) 1996-04-30
GR950300043T1 (en) 1995-07-31
HRP20000295A2 (en) 2000-08-31
RO115164B1 (ro) 1999-11-30
GR3026577T3 (en) 1998-07-31
HRP931410A2 (en) 1996-06-30
LV12212A (lv) 1999-01-20
NO307888B3 (no) 2000-06-13
IS1671B (is) 1997-12-19
JPH07110875B2 (ja) 1995-11-29
HRP931410B1 (en) 2000-06-30
EP0599376B1 (de) 1998-04-08
CY2135B1 (en) 2002-05-21
AU658774B2 (en) 1995-04-27
RU95112521A (ru) 1997-02-10
EP0599376A3 (en) 1994-09-28
ATE177112T1 (de) 1999-03-15
AU5078793A (en) 1994-06-16
SI9300603B (sl) 2004-06-30
ES2052476T1 (es) 1994-07-16
US5886184A (en) 1999-03-23
CZ301191B6 (cs) 2009-12-02
NO305912B1 (no) 1999-08-16
ES2072848T1 (es) 1995-08-01
HU210535A9 (en) 1995-04-28
ES2052476T5 (es) 2008-11-01
CN1090583A (zh) 1994-08-10
DE599376T1 (de) 1994-12-08
FI107450B (fi) 2001-08-15
GR940300045T1 (en) 1994-07-29
US5468860A (en) 1995-11-21
LV12212B (en) 1999-03-20
SK65995A3 (en) 1995-10-11
JP2742409B2 (ja) 1998-04-22
EP0823436A3 (de) 1998-11-25
UA41341C2 (uk) 2001-09-17
FI20010289A (fi) 2001-02-15
NO307888B1 (no) 2000-06-13
EP0823436A2 (de) 1998-02-11
DE69323754T2 (de) 1999-10-07
LV12460B (en) 2000-09-20
ES2052476T3 (es) 1998-06-16
PH31120A (en) 1998-02-23
SI9300603A (en) 1994-06-30
JPH06199889A (ja) 1994-07-19
ES2072848T3 (es) 1999-05-01
CZ287842B6 (en) 2001-02-14
HUT66973A (en) 1995-01-30
HRP20000295B1 (en) 2002-08-31
NO307609B1 (no) 2000-05-02
DE655458T1 (de) 1995-11-30
HU216195B (hu) 1999-05-28
HK1008338A1 (en) 1999-05-07
CA2103107A1 (en) 1994-05-20
CN1058018C (zh) 2000-11-01
HU9303275D0 (en) 1994-03-28
DE69323754D1 (de) 1999-04-08
DZ1733A1 (fr) 2002-02-17
EP0655458B1 (de) 1999-03-03
IS4094A (is) 1994-05-20
ATE164850T1 (de) 1998-04-15
FI114215B (fi) 2004-09-15
NO992580L (no) 1995-05-19
TW257766B (de) 1995-09-21
NO951986L (no) 1995-05-19
FI952422A (fi) 1995-05-18
WO1994011387A3 (en) 1994-09-29
EP0655458A2 (de) 1995-05-31
RU2120445C1 (ru) 1998-10-20
NO992580D0 (no) 1999-05-28
DK0599376T4 (da) 2008-07-28
DE69317856T2 (de) 1998-11-05
EP0655458A3 (de) 1996-07-10
US5652365A (en) 1997-07-29
IL107574A (en) 2000-07-16

Similar Documents

Publication Publication Date Title
DE69317856D1 (de) Ein Verfahren zur Herstellung von Finasteride

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 599376

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 599376

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213